Saturday 17 October 2026
Export HYFT’s income statement to Excel — free account
MindWalk Holdings Corp.
HYFT Healthcare Biotechnology
MindWalk Holdings Corp.’s revenue for fiscal 2026 (year ended April 2026) was $11.3 million, down 35.9% from fiscal 2025. In the quarter to July 2026, revenue grew 19.4%, EPS fell 80.0%, free cash flow grew 9.79% and total debt fell 10.8%, each against the same quarter a year earlier.
1.31
0.09
−6.43%
Follow HYFT
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
5.94 | 5.70 | 4.90 | 5.15 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(42.36) | (35.08) | (31.03) | (20.86) | |
P/B ratio |
6.77 | 7.03 | 6.48 | 12.20 | |
Price to Tangible BV |
14.18 | 18.62 | 29.95 | 0.00 | |
EV/Sales |
5.43 | 5.28 | 4.56 | 5.06 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(11.75) | (8.56) | (5.70) | (6.70) | |
EV/FCF |
(10.80) | (8.02) | (5.52) | (6.59) | |
Quick Ratio |
3.81 | 3.21 | 2.48 | 1.50 | |
Current Ratio |
4.19 | 3.74 | 2.80 | 1.84 | |
Net Debt/EBITDA |
5.16 | 3.18 | 2.02 | 0.79 | |
Debt/Assets |
12.28% | 13.47% | 14.36% | 17.32% | |
Debt/Equity |
0.18 | 0.21 | 0.26 | 0.43 | |
Asset Turnover |
0.46 | 0.54 | 0.48 | 0.56 | |
Operating CF/Net income |
0.89 | 0.76 | 0.63 | 0.66 | |
Capex/Depreciation |
(0.36) | (0.14) | (0.05) | (0.29) | |
Research and Development Expense of Revenue |
29.70% | 29.20% | 35.06% | 33.52% | |
Selling, General and Administrative Expense of Revenue |
102.13% | 118.42% | 130.45% | 184.93% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
3.67% | 6.21% | 19.60% | 19.30% | |
Graham Net Nets |
0.11 | 0.10 | 0.09 | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(32.09%) | (12.35%) | (18.49%) | (20.16%) | |
Free Cash Flow Yield |
(8.47%) | (11.53%) | (16.88%) | (14.90%) | |
Revenue per Share |
0.06 | 0.06 | 0.06 | 0.06 | |
Operating CF per Share |
(0.04) | (0.05) | (0.04) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.05) | (0.04) | (0.06) | |
Cash per Share |
0.26 | 0.22 | 0.18 | 0.12 | |
Shareholders Equity per Share |
0.28 | 0.23 | 0.18 | 0.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.28 | 0.23 | 0.18 | 0.11 | |
Free Cash Flow |
(2.09) | (2.17) | (1.79) | (2.95) | |
Working Capital |
11.92 | 9.94 | 7.56 | 3.99 | |
Capital Expenditures |
(0.05) | (0.02) | (0.01) | (0.06) | |
Net Current Asset Value |
9.61 | 7.71 | 4.78 | 1.29 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.00 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.78 | 2.08 | 2.61 | 1.60 | |
Average Payables |
3.21 | 2.75 | 3.41 | 3.14 | |
Average Inventory |
0.93 | 0.85 | 0.93 | 0.41 | |
Average Assets |
31.36 | 24.30 | 23.69 | 21.03 | |
Average Common Equity |
18.34 | 14.19 | 12.73 | 10.02 |
Columns are period end dates · fundamentals updated 2 Oct 2026